Furthermore, no other compound currently available from UK research suppliers engages all three pathways simultaneously
Contamination: This is a huge one
More serious potential adverse effects include pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury (especially with dehydration), and increased risk of hypoglycemia when used with insulin or sulfonylureas
Another recent study, 344 which examined the impacts of another GLP-1, GIP and GCGR tri-agonist in rodents, found that treatment with this agonist decreased body weight, food intake and hyperglycaemia
2019;25(Suppl 2):1-75
However, based on the populations studied in clinical trials to date, researchers have focused primarily on adults living with obesity typically defined as a body mass index (BMI) of 30 kg/m or above as well as those with overweight accompanied by at least one weight-related health condition, such as type 2 diabetes, hypertension, or dyslipidaemia